Chu de Saint-Etienne
Saint-Etienne, 42055, France
NCT Number: NCT06437847
The prevalence of cognitive disorders is constantly increasing, with 1.2 million patients affected in France in 2016. Dementia is currently the seventh leading cause of death. In the absence of available treatment, systematic screening is not recommended. However, cognitive evaluation is recommended to maintain a level of autonomy for the patient at home. Targeted screening is the responsibility of the general practitioner. The latest recommendations from the HAS (2011) highlight the use of the MMSE as a first-line approach, there are no recommendations regarding short tests. Early cognitive assessment is limited by the time required to perform the tests and the knowledge about the available tools. The Codex is a short test, its sensitivity (92%) and specificity (85%) place it among the most discriminatory scores. It is underutilized in France. The objective of this thesis is to assess the training needs of general practitioners in short tests.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Saint-Etienne, 42055, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Questionnaire assessing the use of cognitive tests.
Time frame: Month : 1, 3, 6
Assessment of the need to use short cognitive tests
Time frame: Month : 1, 3, 6
Assessment of the expectation regarding a project of training general practitioners to use the Codex tool (Sum = 4 or 5: = CODEX normal ; Sum = 0, 1, 2 or 3 = CODEX abnormal)
Centre Hospitalier Universitaire de Saint Etienne
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05220241
COVID-19, Cognition Disorders
Paris, France
View Trial DetailsNCT03205709
Cognition Disorders, Cognitive Decline
New York, United States
View Trial DetailsNCT05568381
Cognition Disorders, Cognitive Disorder
Sydney, New South Wales, Australia
View Trial DetailsNCT03528044
Body Weight, Cognition Disorders
Istanbul, Turkey (Türkiye)
View Trial Details